797801-72-0

Basic information

• Product Name: 2-Piperidinecarboxylic acid, 5-hydroxy-, methyl ester, (2R,5R)-
• Synonyms: (2R,5R)-5-Hydroxy-piperidine-2-carboxylic acid methyl ester;5-(R)-hydroxy-2-(R)-pipecolic acid methyl ester
• CAS NO: 797801-72-0
• Molecular Formula: C7H13NO3
• Molecular Weight: 159.185
• Mol File: 797801-72-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Piperidinecarboxylic acid, 5-hydroxy-, methyl ester, (2R,5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Piperidinecarboxylic acid, 5-hydroxy-, methyl ester, (2R,5R)-(797801-72-0)
• EPA Substance Registry System: 2-Piperidinecarboxylic acid, 5-hydroxy-, methyl ester, (2R,5R)-(797801-72-0)

Safety Data

• Hazardous Substances Data: 797801-72-0(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 448964-01-0 (2R,5R)-5-hydroxypiperidine-2-carboxylic acid 
• 26566-11-0 N-(benzyloxycarbonyl)-D-glutamic acid 1-methyl ester 
• 97975-57-0 (4R)-4-(2-Carboxyethyl)-3-[(phenylmethoxy)carbonyl]oxazolidin-5-one 
• 63648-73-7 N-benzyloxycarbonyl-D-glutamic acid 
• 6893-26-1 D-Glutamic acid 
• 797801-68-4 5-(R)-hydroxy-N-benzyloxycarbonyl-2-(R)-pipecolic acid methyl ester 

Downstream Products

• 1822538-74-8 1-(tert-butyl) 2-methyl (2R,5R)-5-hydroxypiperidine-1,2-dicarboxylate 
• 797801-70-8 1-(N-Boc-aminoethyl)-5-(S)-(N₃-benzoylthymin-1-yl)-2-(R)-pipecolic acid methyl ester 

Relevant articles and documents

(2S,5R/2R,5S)-Aminoethylpipecolyl aepip-aegPNA chimera: Synthesis and duplex/triplex stability

This article reports the design and facile synthesis of novel chiral six-membered PNA analogues (2S,5R/2R,5S)-1-(N-Boc-aminoethyl)-5-(thymin-1-yl) pipecolic acid, aepipPNA IV that upon incorporation into standard aegPNA sequences effected stabilization of

METHODS FOR TREATING HEPATITIS B INFECTIONS

Certain embodiments of the invention provide a method for identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor, such a method comprising detecting a hepatitis B virus (HBV) infected patient's genotype at one or more of the IL28B/A associated SNPs described herein, wherein the relevant genotype(s) described herein are indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations.

TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS

The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).